Recombinant monoclonal antibody to CD22. Clone MJ-7 is a human monoclonal antibody that can be potentially used in the treatment of B-cell malignancy.
Figure 1 Western blot analysis of purified MJ-7.
Size of molecular weight markers are indicated (kDa).
Arndt, M. A., Krauss, J., Schwarzenbacher, R., Vu, B. K., Greene, S., & Rybak, S. M. (2003). Generation of a highly stable, internalizing anti‐CD22 single‐chain Fv fragment for targeting non‐Hodgkin's lymphoma. International journal of cancer, 107(5), 822-829.
Figure 2 Immunoreactivity of monomeric MJ-7 (closed triangle) and MLZ-wt (closed square) after incubation in human serum at 37°C over a period of 6 days.
Arndt, M. A., Krauss, J., Schwarzenbacher, R., Vu, B. K., Greene, S., & Rybak, S. M. (2003). Generation of a highly stable, internalizing anti‐CD22 single‐chain Fv fragment for targeting non‐Hodgkin's lymphoma. International journal of cancer, 107(5), 822-829.
Figure 3 Biophysical stability of IMAC-purified scFv variants.
Immunoreactivity with CD22+ Raji cells was assayed by flow cytometry after incubating the constructs at 37°C in human serum for various time periods. The half-life was determined as the time point with 50% of the initial binding activity.
Arndt, M. A., Krauss, J., Schwarzenbacher, R., Vu, B. K., Greene, S., & Rybak, S. M. (2003). Generation of a highly stable, internalizing anti‐CD22 single‐chain Fv fragment for targeting non‐Hodgkin's lymphoma. International journal of cancer, 107(5), 822-829.
Figure 4 Affinity and specificity of wild-type scFv and stability engineered scFv.
(a) Equilibrium-binding curves for MAb LL2 (open circle); MLZ-wt (closed square) and MJ-7 (closed triangle) as determined by flow cytometry. Binding activity to Raji cells at indicated concentrations is shown as median fluorescence intensity (MFI) minus background fluorescence. Measurements were performed in triplicate; standard deviations are shown as bars. Binding affinity constants (Kd) were determined by fitting the cell binding data to the nonlinear regression model according to the Levenberg-Marquard method. (b) Epitope specificity was determined by competition experiments and analyzed by flow cytometry. MLZ-wt (closed square) and MJ-7 (closed triangle) competed with the MAb LL2 for binding to the CD22 antigen on Raji cells. Results are shown as percent binding inhibition of MAb LL2 at a concentration of 100 nM when incubating tumor cells with various concentrations of scFvs.
Arndt, M. A., Krauss, J., Schwarzenbacher, R., Vu, B. K., Greene, S., & Rybak, S. M. (2003). Generation of a highly stable, internalizing anti‐CD22 single‐chain Fv fragment for targeting non‐Hodgkin's lymphoma. International journal of cancer, 107(5), 822-829.
Figure 5 Internalization of antibodies into living tumor cells.
Alexa-488-labeled MAb LL2 (a,b) or scFv MJ-7 (c,d), each at a concentration of 50 μg/ml, were incubated with Raji cells (5 × 10⁵) for 30 min either at 4°C (a,c) or 37°C (b,d) before analysis by confocal microscopy.
Arndt, M. A., Krauss, J., Schwarzenbacher, R., Vu, B. K., Greene, S., & Rybak, S. M. (2003). Generation of a highly stable, internalizing anti‐CD22 single‐chain Fv fragment for targeting non‐Hodgkin's lymphoma. International journal of cancer, 107(5), 822-829.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-1248z-S(P) | Recombinant Anti-Human CD22 Antibody scFv Fragment | ELISA, WB, IF, FuncS | scFv |
HPAB-N0324-YC-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (HPAB-N0324-YC-S(P)) | FuncS | Mouse scFv |
HPAB-N0325-YC-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (HPAB-N0325-YC-S(P)) | FuncS | Mouse scFv |
HPAB-0249-FY-S(P) | Recombinant Human Anti-CD22 Antibody scFv Fragment | F | Human scFv |
HPAB-2052-FY-S(P) | Human Anti-CD22 Recombinant Antibody (clone B28); scFv Fragment | FC | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-899 | Humanized Anti-CD22 Recombinant Antibody (clone Pinatuzumab) | FC, IP, ELISA, Neut, FuncS, IF, ICC | Humanized (from mouse) IgG1, κ |
TAB-1725CL | Human Anti-CD22 Recombinant Antibody (TAB-1725CL) | Block, Cyt, ELISA, FuncS | Humanized IgG |
TAB-1729CL | Human Anti-CD22 Recombinant Antibody (TAB-1729CL) | IF, FC | Humanized IgG |
TAB-002LC-S(P) | Anti-Human CD22 Recombinant Antibody scFv Fragment (VM1000) | ELISA, SPR | Humanized antibody |
TAB-002LC-F(E) | Anti-Human CD22 Recombinant Antibody Fab Fragment (VM1000) | ELISA, SPR | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-G077E | Anti-CD22 immunotoxin RFB4 (IgG)-PE | Cytotoxicity assay, Function study | |
AGTO-G077D | Anti-CD22 immunotoxin RFB4 (IgG)-DT | Cytotoxicity assay, Function study | |
AGTO-G077G | Anti-CD22 immunotoxin RFB4 (IgG)-Gel | Cytotoxicity assay, Function study | |
AGTO-G077R | Anti-CD22 immunotoxin RFB4 (IgG)-RTA | Cytotoxicity assay, Function study | |
AGTO-G077S | Anti-CD22 immunotoxin RFB4 (IgG)-Sap | Cytotoxicity assay, Function study |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0196CL | Anti-Human CD22 Recombinant Antibody (hLL2) | Inhib, Cyt, FC, WB | |
TAB-0197CL | Anti-Human CD22 Recombinant Antibody (hLL2-Cys) | ELISA, In vivo | |
TAB-1715CL | Anti-Human CD22 Recombinant Antibody (12C5) | Cyt, FuncS | Fully human antibody |
TAB-1721CL-S(P) | Anti-Human CD22 Recombinant Antibody scFv Fragment (CD22.1) | ELISA, FC, FuncS | Human antibody |
TAB-1722CL-S(P) | Anti-Human CD22 Recombinant Antibody scFv Fragment (CD22.2) | ELISA, FC, FuncS | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1724CL | Human Anti-CD22 Recombinant Antibody (TAB-1724CL) | Inhib | Chimeric (mouse/human) IgG1, κ |
TAB-1724CL-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-1724CL-F(E)) | Inhib | Chimeric (mouse/human) Fab |
TAB-001LC | Human Anti-CD22 Recombinant Antibody (TAB-001LC) | ELISA | Chimeric antibody (mouse/human) |
TAB-001LC-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-001LC-S(P)) | ELISA | Mouse scFv |
TAB-001LC-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-001LC-F(E)) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1714CL-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-1714CL-S(P)) | ELISA, WB | Mouse scFv |
TAB-1723CL-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-1723CL-S(P)) | Inhib | Mouse scFv |
TAB-1728CL-S(P) | Anti-Human CD22 Recombinant Antibody scFv Fragment (RFB4) | IF, FC | |
TAB-003LC | Mouse Anti-Human CD22 Recombinant Antibody | FC | |
TAB-004LC | Anti-Human CD22 Recombinant Antibody | FC |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-001LC | Recombinant Anti-Human CD22 Antibody (Fab glycosylation) | ELISA, FC | Mouse antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-111LC | Recombinant Anti-Human CD22 Antibody (Fc glycosylation) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-0349MZ | Mouse Anti-CD22 Recombinant Antibody (clone 5LB129) | ELISA | Mouse IgG1 |
HPAB-0195-LSX | Human Anti-CD22 Recombinant Antibody (HPAB-0195-LSX) | Apop, Cyt, FC, WB, Inhib, FuncS, IF, ELISA | Human IgG |
HPAB-0196-LSX | Mouse Anti-CD22 Recombinant Antibody (HPAB-0196-LSX) | ELISA, FC, IP, RIA | Mouse IgG |
HPAB-0197-LSX | Human Anti-CD22 Recombinant Antibody (HPAB-0197-LSX) | ELISA, FC, FuncS | Human IgG |
HPAB-0198-LSX | Mouse Anti-CD22 Recombinant Antibody (HPAB-0198-LSX) | ELISA, WB, IF, FC, SPR | Mouse IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-315CQ | Rat Anti-CD22 Recombinant Antibody (clone 2D6) | Block | Rat IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-0545 | Hi-Affi™ Rabbit Anti-CD22 Recombinant Antibody (clone DS545AB) | IP, WB | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0194-LSX-F(E) | Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0194-LSX-F(E)) | ELISA | Mouse Fab |
HPAB-0195-LSX-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0195-LSX-F(E)) | ELISA | Human Fab |
HPAB-0196-LSX-F(E) | Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0196-LSX-F(E)) | ELISA | Mouse Fab |
HPAB-0197-LSX-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0197-LSX-F(E)) | ELISA | Human Fab |
HPAB-0198-LSX-F(E) | Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0198-LSX-F(E)) | ELISA, FC | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-176 | Afuco™ Anti-CD22 ADCC Recombinant Antibody (Epratuzumab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-198 | Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
There are currently no Customer reviews or questions for HPAB-0206-LSX. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.